At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
Camostat Mesilate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor
In Brief
A Phase 2 clinical trial evaluating Camostat Mesilate and Standard of Care for Severe Acute Respiratory Syndrome. Completed, enrolled 100 participants across 2 sites.
Detailed Summary
To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Acute Respiratory Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartJul 2020
Primary CompletionDec 2021
Study CompletionJan 2022
TodayJul 2026
First PostedJul 14, 2020
Enrollment StartJul 28, 2020
Primary CompletionDec 22, 2021
Study CompletionJan 20, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.0 years ago
Interventions
Camostat Mesilatedrug
Given PO
Standard of Careother
At Investigator discretion